This is a possible mechanism by which reduction of CTNNB1 expression by PPARγ agonists could contribute to inhibition of the loss of cellular attachments, as well as reducing the transcription of tumor-promoting target genes of CTNNB1 such as CCND1 and MYC (28). This evidence concerns the gene CTNNB1 and neoplasm.